{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:52:28Z","timestamp":1792266748759,"version":"4.4.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1053\/j.seminhematol.2016.05.009","type":"journal-article","created":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T18:38:18Z","timestamp":1463164698000},"page":"190-202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Nodular lymphocyte-predominant Hodgkin lymphoma"],"prefix":"10.1053","volume":"53","author":[{"given":"Kerry J.","family":"Savage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Mottok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Fanale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1053\/j.seminhematol.2016.05.009_bib1","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.1999.17.3.776","article-title":"Clinical presentation, course, and prognostic factors in lymphocyte predominant Hodgkin\u2019s disease and lymphocyte-rich classical Hodgkin\u2019s disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin\u2019s Disease","volume":"17","author":"Diehl","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.009_bib2","unstructured":"Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissue, 4th ed. IARC; 2008."},{"issue":"3","key":"10.1053\/j.seminhematol.2016.05.009_bib3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/path.1894","article-title":"Cytokine gene expression profile distinguishes CD4+\/CD57+ T cells of the nodular lymphocyte predominance type of Hodgkin\u2019s lymphoma from their tonsillar counterparts","volume":"208","author":"Atayar","year":"2006","journal-title":"J Pathol"},{"issue":"7","key":"10.1053\/j.seminhematol.2016.05.009_bib4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/ajh.21434","article-title":"Differentiating germinal center-derived lymphomas through their cellular microenvironment","volume":"84","author":"Carbone","year":"2009","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1053\/j.seminhematol.2016.05.009_bib5","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1097\/PAS.0b013e31822832de","article-title":"Nodular lymphocyte-predominant hodgkin lymphoma with atypical T cells: a morphologic variant mimicking peripheral T-cell lymphoma","volume":"35","author":"Sohani","year":"2011","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1053\/j.seminhematol.2016.05.009_bib6","first-page":"1889","article-title":"European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes","volume":"96","author":"Anagnostopoulos","year":"2000","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2016.05.009_bib7","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/modpathol.3800622","article-title":"Expression profiling of transcription factors Pax-5, Oct-1, Oct-2, BOB.1, and PU.1 in Hodgkin\u2019s and non-Hodgkin\u2019s lymphomas: a comparative study using high throughput tissue microarrays","volume":"19","author":"McCune","year":"2006","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1053\/j.seminhematol.2016.05.009_bib8","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/path.1746","article-title":"Differential expression of activation-induced cytidine deaminase (AID) in nodular lymphocyte-predominant and classical Hodgkin lymphoma","volume":"205","author":"Greiner","year":"2005","journal-title":"J Pathol"},{"issue":"10","key":"10.1053\/j.seminhematol.2016.05.009_bib9","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1084\/jem.20080809","article-title":"Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis","volume":"205","author":"Brune","year":"2008","journal-title":"J Exp Med"},{"issue":"4","key":"10.1053\/j.seminhematol.2016.05.009_bib10","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/path.2242","article-title":"Selective loss of B-cell phenotype in lymphocyte predominant Hodgkin lymphoma","volume":"213","author":"Tedoldi","year":"2007","journal-title":"J Pathol"},{"issue":"10","key":"10.1053\/j.seminhematol.2016.05.009_bib11","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1097\/00000478-200310000-00007","article-title":"Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation","volume":"27","author":"Fan","year":"2003","journal-title":"Am J Surg Pathol"},{"issue":"26","key":"10.1053\/j.seminhematol.2016.05.009_bib12","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1182\/blood-2013-07-515825","article-title":"The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)","volume":"122","author":"Hartmann","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2016.05.009_bib13","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1182\/blood-2007-03-082511","article-title":"Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6","volume":"110","author":"Mottok","year":"2007","journal-title":"Blood"},{"issue":"18","key":"10.1053\/j.seminhematol.2016.05.009_bib14","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1038\/sj.onc.1209151","article-title":"Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation","volume":"25","author":"Weniger","year":"2006","journal-title":"Oncogene"},{"issue":"1","key":"10.1053\/j.seminhematol.2016.05.009_bib15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3324\/haematol.2009.010157","article-title":"Mutations in the genes coding for the NF-kappaB regulating factors IkappaBalpha and A20 are uncommon in nodular lymphocyte-predominant Hodgkin\u2019s lymphoma","volume":"95","author":"Schumacher","year":"2010","journal-title":"Haematologica"},{"issue":"2","key":"10.1053\/j.seminhematol.2016.05.009_bib16","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1182\/blood-2002-05-1592","article-title":"Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma","volume":"101","author":"Wlodarska","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2016.05.009_bib17","doi-asserted-by":"crossref","unstructured":"Hartmann S, Schuhmacher B, Rausch T, et al. Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma. Leukemia. 2015 Dec 10. PubMed PMID: 26658840.","DOI":"10.1038\/leu.2015.328"},{"key":"10.1053\/j.seminhematol.2016.05.009_bib18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/00000478-198404000-00002","article-title":"Differential diagnostic features of nodular L&H Hodgkin\u2019s disease, including progressive transformation of germinal centers","volume":"8","author":"Burns","year":"1984","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1053\/j.seminhematol.2016.05.009_bib19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/ajcp\/93.2.219","article-title":"Progressive transformation of germinal centers with and without association to Hodgkin\u2019s disease","volume":"93","author":"Hansmann","year":"1990","journal-title":"Am J Clin Pathol"},{"issue":"11","key":"10.1053\/j.seminhematol.2016.05.009_bib20","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.humpath.2015.07.006","article-title":"Immunoarchitectural patterns of progressive transformation of germinal centers with and without nodular lymphocyte-predominant Hodgkin lymphoma","volume":"46","author":"Hartmann","year":"2015","journal-title":"Hum Pathol"},{"issue":"12","key":"10.1053\/j.seminhematol.2016.05.009_bib21","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/j.humpath.2010.05.010","article-title":"Programmed death 1 expression in variant immunoarchitectural patterns of nodular lymphocyte predominant Hodgkin lymphoma: comparison with CD57 and lymphomas in the differential diagnosis","volume":"41","author":"Churchill","year":"2010","journal-title":"Hum Pathol"},{"issue":"6","key":"10.1053\/j.seminhematol.2016.05.009_bib22","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1182\/blood.V86.6.2312.bloodjournal8662312","article-title":"Clonal relationship between lymphocytic predominance Hodgkin\u2019s disease and concurrent or subsequent large-cell lymphoma of B lineage","volume":"86","author":"Wickert","year":"1995","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2016.05.009_bib23","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood.V97.6.1845","article-title":"Lymphocyte predominance Hodgkin disease is characterized by recurrent genomic imbalances","volume":"97","author":"Franke","year":"2001","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2016.05.009_bib24","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/bjh.13310","article-title":"Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell\/histiocyte rich large B cell lymphoma","volume":"169","author":"Hartmann","year":"2015","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1053\/j.seminhematol.2016.05.009_bib25","doi-asserted-by":"crossref","first-page":"e78812","DOI":"10.1371\/journal.pone.0078812","article-title":"Nodular lymphocyte predominant hodgkin lymphoma and T cell\/histiocyte rich large B cell lymphoma\u2014endpoints of a spectrum of one disease?","volume":"8","author":"Hartmann","year":"2013","journal-title":"PloS One"},{"issue":"3","key":"10.1053\/j.seminhematol.2016.05.009_bib26","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3324\/haematol.2009.009647","article-title":"T-cell\/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response","volume":"95","author":"Van Loo","year":"2010","journal-title":"Haematologica"},{"issue":"5","key":"10.1053\/j.seminhematol.2016.05.009_bib27","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2009.24.9516","article-title":"Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin\u2019s lymphoma","volume":"28","author":"Al-Mansour","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2016.05.009_bib28","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.24819","article-title":"Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group","volume":"116","author":"Biasoli","year":"2010","journal-title":"Cancer"},{"issue":"3-4","key":"10.1053\/j.seminhematol.2016.05.009_bib29","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3109\/10428199709051786","article-title":"Nodular lymphocyte predominance Hodgkin\u2019s disease: long-term observation reveals a continuous pattern of recurrence","volume":"26","author":"Orlandi","year":"1997","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1053\/j.seminhematol.2016.05.009_bib30","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.2013.53.2069","article-title":"Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma","volume":"32","author":"Advani","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2016.05.009_bib31","doi-asserted-by":"crossref","first-page":"E103","DOI":"10.1002\/ajh.23989","article-title":"Incidence, management, and outcome of high-grade transformation of nodular lymphocyte predominant Hodgkin lymphoma: long-term outcomes from a 30-year experience","volume":"90","author":"Eyre","year":"2015","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1053\/j.seminhematol.2016.05.009_bib32","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1200\/JCO.2001.19.7.2026","article-title":"Non-Hodgkin\u2019s lymphoma after primary Hodgkin\u2019s disease in the German Hodgkin\u2019s Lymphoma Study Group: incidence, treatment, and prognosis","volume":"19","author":"Rueffer","year":"2001","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2016.05.009_bib33","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/annonc\/mdl496","article-title":"Phase I\/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin\u2019s lymphoma","volume":"18","author":"Evens","year":"2007","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2016.05.009_bib34","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1182\/blood.V88.2.657.bloodjournal882657","article-title":"Nodular lymphocyte-predominant Hodgkin\u2019s disease associated with large-cell lymphoma: analysis of Ig gene rearrangements by V-J polymerase chain reaction","volume":"88","author":"Greiner","year":"1996","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2016.05.009_bib35","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1309\/KY8C-LCYN-QHJ6-4C6R","article-title":"The tumor cells in nodular lymphocyte-predominant Hodgkin disease are clonally related to the large cell lymphoma occurring in the same individual. Direct demonstration by single cell analysis","volume":"116","author":"Ohno","year":"2001","journal-title":"Am J Clin Pathol"},{"issue":"Suppl 3","key":"10.1053\/j.seminhematol.2016.05.009_bib36","doi-asserted-by":"crossref","first-page":"iii70","DOI":"10.1093\/annonc\/mdu181","article-title":"Hodgkin\u2019s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Eichenauer","year":"2014","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2016.05.009_bib37","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/cncr.21303","article-title":"Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group","volume":"104","author":"Wirth","year":"2005","journal-title":"Cancer"},{"issue":"1","key":"10.1053\/j.seminhematol.2016.05.009_bib38","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2009.24.0945","article-title":"Early-stage, lymphocyte-predominant Hodgkin\u2019s lymphoma: patient outcomes from a large, single-institution series with long follow-up","volume":"28","author":"Chen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1053\/j.seminhematol.2016.05.009_bib39","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin\u2019s lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1053\/j.seminhematol.2016.05.009_bib40","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.2004.12.170","article-title":"ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin\u2019s disease: long-term results","volume":"22","author":"Bonadonna","year":"2004","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1053\/j.seminhematol.2016.05.009_bib41","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1200\/JCO.2007.15.1001","article-title":"Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin\u2019s lymphoma: a question of field size","volume":"26","author":"Campbell","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2016.05.009_bib42","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2016.05.009_bib43","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Hodgkin Lymphoma Vervsion 2.2015. wwwnccnorg. 2015."},{"issue":"4","key":"10.1053\/j.seminhematol.2016.05.009_bib44","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"23","key":"10.1053\/j.seminhematol.2016.05.009_bib45","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1200\/JCO.2006.07.0482","article-title":"Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin\u2019s lymphoma: final results of the GHSG HD7 trial","volume":"25","author":"Engert","year":"2007","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1053\/j.seminhematol.2016.05.009_bib46","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa064601","article-title":"Chemotherapy plus involved-field radiation in early-stage Hodgkin\u2019s disease","volume":"357","author":"Ferme","year":"2007","journal-title":"N Engl J Med"},{"issue":"9976","key":"10.1053\/j.seminhematol.2016.05.009_bib47","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S0140-6736(14)61469-0","article-title":"Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin\u2019s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial","volume":"385","author":"Behringer","year":"2015","journal-title":"Lancet"},{"issue":"9","key":"10.1053\/j.seminhematol.2016.05.009_bib48","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood-2004-02-0567","volume":"104","author":"Feugier","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2016.05.009_bib49","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.2007.11.8869","article-title":"Lymphocyte-predominant and classical Hodgkin\u2019s lymphoma: a comprehensive analysis from the German Hodgkin Study Group","volume":"26","author":"Nogova","year":"2008","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1053\/j.seminhematol.2016.05.009_bib50","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1200\/JCO.2014.60.4363","article-title":"Long-term course of patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group","volume":"33","author":"Eichenauer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1053\/j.seminhematol.2016.05.009_bib51","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1182\/blood-2011-07-365932","article-title":"Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome","volume":"118","author":"Savage","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2016.05.009_bib52","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1002\/cncr.10404","article-title":"European Organization for Research and Treatment of Cancer and Groupe d\u2019Etude des Lymphomes de l\u2019Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease","volume":"94","author":"Wilder","year":"2002","journal-title":"Cancer"},{"issue":"12","key":"10.1053\/j.seminhematol.2016.05.009_bib53","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3324\/haematol.2015.133025","article-title":"Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study","volume":"100","author":"Lazarovici","year":"2015","journal-title":"Haematologica"},{"issue":"11","key":"10.1053\/j.seminhematol.2016.05.009_bib54","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.ejca.2011.10.018","article-title":"Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin\u2019s lymphoma\u2014an Anglo-French collaborative report","volume":"48","author":"Shankar","year":"2012","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1053\/j.seminhematol.2016.05.009_bib55","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1200\/JCO.2006.08.4772","article-title":"Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin\u2019s disease","volume":"25","author":"Donaldson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1053\/j.seminhematol.2016.05.009_bib56","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1200\/JCO.2011.41.1819","article-title":"Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin\u2019s lymphoma\u2014a report from the Children\u2019s Oncology Group","volume":"30","author":"Wolden","year":"2012","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2016.05.009_bib57","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/pbc.24258","article-title":"Impact of low-dose involved-field radiation therapy on pediatric patients with lymphocyte-predominant Hodgkin lymphoma treated with chemotherapy: a report from the Children\u2019s Oncology Group","volume":"59","author":"Appel","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"21","key":"10.1053\/j.seminhematol.2016.05.009_bib58","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin\u2019s disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2016.05.009_bib59","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1200\/JCO.2009.26.3293","article-title":"What is the appropriate systemic chemotherapy for lymphocyte-predominant Hodgkin\u2019s lymphoma?","volume":"28","author":"Canellos","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2016.05.009_bib60","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/cncr.22762","article-title":"Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma\u2014experience from the European network group on pediatric Hodgkin lymphoma","volume":"110","author":"Mauz-Korholz","year":"2007","journal-title":"Cancer"},{"issue":"Suppl","key":"10.1053\/j.seminhematol.2016.05.009_bib61","article-title":"Treatment of pediatric stage 1A lymphocyte predominant Hodgkin lymphoma with surgical resection alone: A report from the Children\u2019s Oncology Group","volume":"30","author":"Appel","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2016.05.009_bib62","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1093\/annonc\/mdq063","article-title":"Lymphocyte-predominant Hodgkin lymphoma\u2014clinical features and treatment outcomes from a 30-year experience","volume":"21","author":"Jackson","year":"2010","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2016.05.009_bib63","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/JCO.2003.12.086","article-title":"Randomized comparison of ABVD and MOPP\/ABV hybrid for the treatment of advanced Hodgkin\u2019s disease: report of an intergroup trial","volume":"21","author":"Duggan","year":"2003","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1053\/j.seminhematol.2016.05.009_bib64","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1182\/blood-2013-12-541078","article-title":"Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis","volume":"123","author":"Xing","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2016.05.009_bib65","article-title":"Rituximab-ABV(D) for patients with nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy","author":"Garciaz","year":"2015","journal-title":"Br J Haematol"},{"issue":"26","key":"10.1053\/j.seminhematol.2016.05.009_bib66","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1182\/blood-2013-07-453241","article-title":"How I treat nodular lymphocyte predominant Hodgkin lymphoma","volume":"122","author":"Advani","year":"2013","journal-title":"Blood"},{"issue":"21","key":"10.1053\/j.seminhematol.2016.05.009_bib67","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.2812.2812","article-title":"Outcomes of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) in patients treated with R-CHOP","volume":"116","author":"Fanale","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2016.05.009_bib68","series-title":"Hodgkin\u2019s disease","first-page":"563","article-title":"Clinical presentation and treatment of lymphocyte predominance Hodgkin\u2019s disease","author":"Diehl","year":"1999"},{"issue":"9323","key":"10.1053\/j.seminhematol.2016.05.009_bib69","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"issue":"6","key":"10.1053\/j.seminhematol.2016.05.009_bib70","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.bbmt.2013.03.008","article-title":"High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma","volume":"19","author":"Karuturi","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1053\/j.seminhematol.2016.05.009_bib71","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00277-015-2527-4","article-title":"High-dose chemotherapy and autologous stem cell transplantation for relapsed or refractory nodular lymphocyte predominant Hodgkin lymphoma","volume":"95","author":"Akhtar","year":"2016","journal-title":"Ann Hematol"},{"issue":"16","key":"10.1053\/j.seminhematol.2016.05.009_bib72","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1182\/blood-2011-06-361055","article-title":"Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group","volume":"118","author":"Eichenauer","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2016.05.009_bib73","doi-asserted-by":"crossref","unstructured":"Hall GW, Katzilakis N, Pinkerton CR, Nicolin G, Ashley S, McCarthy K, Daw S, Hewitt M, Wallace WH, Shankar A. Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma - a Children\u2019s Cancer and Leuka 2007","DOI":"10.1111\/j.1365-2141.2007.06736.x"},{"key":"10.1053\/j.seminhematol.2016.05.009_bib74","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/annonc\/mdi323","article-title":"Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: A retrospective analysis from the German Hodgkin Study Group (GHSG)","volume":"16","author":"Nogova","year":"2005","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology \/ ESMO"},{"issue":"6","key":"10.1053\/j.seminhematol.2016.05.009_bib75","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/COC.0b013e318145b9db","article-title":"Clinical presentation and outcomes of lymphocyte predominant Hodgkin disease at the University of Florida","volume":"30","author":"Chera","year":"2007","journal-title":"Am J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2016.05.009_bib76","doi-asserted-by":"crossref","unstructured":"Farrell, K, McKay P, Leach M. Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14 year follow-up in the West of Scotland Cancer Network. Leukemia and Lymphoma, October 11; 52(10): 1920-8.","DOI":"10.3109\/10428194.2011.584993"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196316300464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196316300464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:24:42Z","timestamp":1758522282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196316300464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":76,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0037196316300464"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2016.05.009","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nodular lymphocyte-predominant Hodgkin lymphoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2016.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}